Mestag Therapeutics
PrivateLast Round
VC Round
Mar 17, 2026
Total Funding Raised
$46.9M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Mestag Therapeutics operates in Healthcare & Life Sciences and is based in Cambridge. Its latest recorded funding round was a VC Round in March 2026.
Mestag Therapeutics is a biotechnology company that develops first-in-class immunotherapies targeting fibroblast-immune interactions to treat cancer and inflammatory diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Mestag Therapeutics Comparables
Compare Mestag Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Macomics | 77% | |
| Agni Bio, Inc. | 77% | |
| F-star Therapeutics | 77% |
For institutional investors. Book with your work email.
Mestag Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Mar 17, 2026 | ||||
| Grant | Aug 28, 2024 | ||||
| Seed | Aug 3, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Mestag Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forbion Capital Partners | VC Round |
| SV Health Investors | VC Round, Seed |
| GV | VC Round, Seed |
| Forbion | VC Round, Seed |
| Northpond Ventures | VC Round, Seed |
| Johnson & Johnson Innovation - JJDC | VC Round |
| Innovate UK | Grant |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 90% MoM.
- Mar 17, 2026
$40M raised in early funding.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresOct 20, 2026
Mestag Therapeutics Limited appoints Philip Astley-Sparke to its Board of Directors in the United Kingdom on Oct 20th '26, alongside Victor Sandor, M.D.C.M.
- hiresOct 20, 2026
Mestag Therapeutics Limited appoints Philip Astley-Sparke and Victor Sandor, M.D.C.M., to its Board of Directors in the United Kingdom on Oct 20th '26, strengthening its clinical, regulatory and strategic expertise as it advances the Phase 1 STARLYS trial.
- hiresOct 20, 2026
Mestag Therapeutics Limited appoints Victor Sandor, M.D.C.M., as a member of its Board of Directors in the United Kingdom on Oct 20th '26, alongside Philip Astley-Sparke, strengthening its clinical, regulatory and strategic expertise.
For institutional investors. Book with your work email.
Mestag Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Mestag Therapeutics's valuation, stock price, and market status.
Is Mestag Therapeutics a public or private company?
Mestag Therapeutics is a private company.
What is the current stock price of Mestag Therapeutics?
Mestag Therapeutics is a private company, so its shares have no public market price. Caplight tracks Mestag Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Mestag Therapeutics worth (valuation)?
Valuation information for Mestag Therapeutics is not publicly available.
Can I buy Mestag Therapeutics stock?
Mestag Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Mestag Therapeutics's last funding round?
Mestag Therapeutics's most recent funding round was VC Round on March 17, 2026.
Who are the main investors in Mestag Therapeutics?
Key investors in Mestag Therapeutics include Forbion, Johnson & Johnson Innovation - JJDC.
Will Mestag Therapeutics IPO soon?
No public IPO plans have been announced for Mestag Therapeutics.
How can I track Mestag Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Mestag Therapeutics's shares on secondary markets.